Actionable news
All posts from Actionable news
Actionable news in PFE: PFIZER Inc,

How Can Pfizer's Drugs, Trials, And Acquisitions Grow Sales?

Pharmaceutical giant Pfizer Inc. PFE 1.11% raised its earnings and revenue outlook for 2016 when it announced Q1 results earlier this year. Analysts are waiting to hear if that’s still on track when PFE reports Q2 results ahead of the bell Tuesday.

Analysts also say that products like Eliquis, Xalkori, Xeljanz, Ibrance and Prevnar 13 could boost top-line sales “meaningfully,” while recent cost savings might help the bottom line. What else is in the pipeline? The recent acquisition of Hospira also is expected to contribute to growth. How is that integration going?

Last week, PFE won bankruptcy-court approval to purchase the assets of Bind Therapeutics, which develops cancer drug treatments that analysts say they’ll also want to know more about. Also of interest is PFE’s recent announcement of positive top-line results from oral trials tied to a drug treating moderately to severely active ulcerative colitis.

Analysts reporting to Thomson Reuters expect earnings per share of $0.62 on revenues of $13 billion. A year ago, PFE turned in a profit of $0.56 a share on topline sales of $11.9 billion.

Short-term options traders have priced in a potential 2.5% share price move in either direction around the earnings release, according to the Market Maker Move™ indicator on the thinkorswim® platform from TD Ameritrade.

Options trading was generally light last week, but there was some volume in the 36- and 36.5-strike puts. Volume on the call side was light as well, but some trading was taking place in the 36.5- and 37-strike lines. The implied volatility is at the 24th percentile. (Please remember past performance is no guarantee of future results.)

Note: Call options represent the right, but not the obligation, to buy the underlying security at a predetermined price over a set period of time. Put options represent the right, but not the obligation, to sell the underlying security at a predetermined price over a set period of time.

Probability analysis results from the Market Maker Move indicator are theoretical in nature, not guaranteed, and do not reflect any degree of certainty of an event occurring.

TD Ameritrade and all third parties mentioned are separate and unaffiliated companies, and are not responsible for each other’s policies or services. Inclusion of specific security names in this commentary does not constitute a recommendation from TD Ameritrade to buy, sell, or hold. Market volatility, volume, and system availability may delay account access and trade executions. Past performance of a security or strategy does not guarantee future results or success. Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses. Options trading subject to TD Ameritrade review and approval. Please read Characteristics and Risks of Standardized Options before investing in options. Supporting documentation for any claims, comparisons, statistics, or other technical data will be supplied upon request. The information is not intended to be investment advice or construed as a recommendation or endorsement of any particular investment or investment strategy, and is for illustrative purposes only. Be sure to understand all risks involved with each strategy, including commission costs, before attempting to place any trade. Clients must consider all relevant risk factors, including their own personal financial situations, before trading.< TD Ameritrade, Inc., member FINRA/SIPC. TD Ameritrade is a trademark jointly owned by TD Ameritrade IP Company, Inc. and The Toronto-Dominion Bank. © 2016 TD Ameritrade IP Company, Inc. All rights reserved. Used with permission.

© 2016 Benzinga does not provide investment advice. All rights reserved.